(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $54 to $94, according to analysts polled by Capital IQ. (MT...
David M Stack, Director, Chief Executive Officer and Chairman, on June 06, 2022, sold 25,793 shares in Pacira Biosciences (PCRX) for $1,561,998. Following...
Roy Winston, Chief Medical Officer, on June 06, 2022, sold 17,546 shares in Pacira Biosciences (PCRX) for $1,077,135. Following the Form 4 filing with the...
| Address | 5401 West Kennedy Boulevard Tampa, Florida 33609 |
| Phone | +1.813.553.6680 |
| Number of Employees | 518 |
| Recent SEC Filing | 06/16/2022 4 |
| Chairman & Chief Executive Officer | David M. Stack |
| Chief Operating Officer | Daryl J. Gaugler |
| Chief Financial Officer | Charles A. Reinhart |
| Chief Medical Officer | Roy Winston |
| Price Open | $57.90 |
| Previous Close | $58.30 |
| 52 Week Range | $45.05 - 82.16 |
| Market Capitalization | $2.6 B |
| Shares Outstanding | 45.4 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 68.87 |
| Earnings per Share | $1.53 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 6.62% |
| Return on Equity | 5.40% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
